Online citations, reference lists, and bibliographies.
← Back to Search

Double-blind, Right/left Comparison Of Calcipotriol And Betamethasone Valerate In Treatment Of Psoriasis Vulgaris

K. Kragballe, B. Gjertsen, D. Hoop, P. Kerkhof, G. Tikjøb
Published 1991 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The therapeutic efficacy and tolerability of calcipotriol ointment and betamethasone valerate ointment in psoriasis were compared in a multicentre, prospective, randomised, double-blind, right/left trial. 345 inpatients and outpatients with psoriasis vulgaris of symmetrical distribution were treated twice daily for 6 weeks with calcipotriol ointment 50 micrograms/g and betamethasone ointment 0.1% randomly assigned to opposite sides of the body. The main outcome measures--the psoriasis area and severity index (PASI), the investigators' assessments of erythema, thickness, and scaling, and the patients' own assessments of the overall response to treatment--were sought at weeks 2, 4, and 6. Both treatments significantly reduced the PASI scores and the investigator's assessment scores, but at each visit the PASI score was significantly (p less than 0.001) lower with calcipotriol than with betamethasone. At 6 weeks the mean PASI reduction was 68.8% with calcipotriol and 61.4% with betamethasone (95% confidence interval for difference 5.1-9.8, p less than 0.001). The scores for erythema, thickness, and scaling were significantly (p less than 0.001) lower with calcipotriol than with betamethasone at the end of treatment. The patients considered that 82.1% of calcipotriol-treated sides and 69.3% of betamethasone-treated sides had improved greatly or cleared up by the end of treatment (p less than 0.001). 57 adverse events were reported by 52 patients (15.1%). The most common adverse event, lesional/perilesional skin irritation, was slightly but not significantly (p = 0.12) more common with calcipotriol treatment. 15 (4.3%) patients were withdrawn from the study, 3 because of local adverse events. There were no changes in serum calcium during the study. Thus, calcipotriol ointment was superior to betamethasone valerate ointment in psoriasis vulgaris. Though long-term results are not yet available, calcipotriol holds great promise as an antipsoriatic agent.
This paper references
10.1111/j.1365-2133.1989.tb01353.x
A double‐blind study of topical 1α,25‐dihydroxyvitamin D3 in psoriasis
P. Kerkhof (1989)
10.1016/S0040-4020(01)86903-9
Synthesis of mc 903, a biologically active vitamin D metabolite analogue
M. Calverley (1987)
10.1111/1523-1747.EP12276343
Effect of 1α,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions
E. Smith (1986)
10.1111/j.1365-2133.1986.tb06236.x
An open study of vitamin D3 treatment in psoriasis vulgaris
S. Morimoto (1986)
10.1016/S0190-9622(88)70207-8
A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis.
E. Smith (1988)
10.1210/JCEM-56-4-824
Interaction of 1,25-dihydroxyvitamin-D3 with keratinocytes and fibroblasts from skin of normal subjects and a subject with vitamin-D-dependent rickets, type II: a model for study of the mode of action of 1,25-dihydroxyvitamin D3.
T. Clemens (1983)
10.1111/j.1365-2133.1989.tb15517.x
A double‐blind, placebo‐controlled trial of topical 1,25‐dihydroxycholecalciferol in psoriasis
C. A. Henderson (1989)
10.1111/j.1365-2133.1988.tb03204.x
Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double‐blind study
K. Kragballe (1988)
10.1159/000250839
Severe psoriasis--oral therapy with a new retinoid.
T. Fredriksson (1978)
10.1001/ARCHDERM.1989.01670240047011
Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903)
K. Kragballe (1989)
10.1210/JCEM-57-6-1308
Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation.
A. Bhalla (1983)
10.1016/0006-2952(88)90177-3
Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo.
L. Binderup (1988)
10.1530/ACTA.0.114S094
1,25-Dihydroxyvitamin D3 action and receptors in endothelial and smooth muscle cells of arterial vessels
J. Merke (1987)



This paper is referenced by
10.3109/09546639609089562
What is new in the treatment of psoriasis
P. Kerkhof (1996)
10.1111/j.1365-2133.1996.tb07608.x
Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis
A. Pérez (1996)
10.2336/NISHINIHONHIFU.74.189
尋常性乾癬治療におけるドボネックス®50μg/g軟膏の併用による患者満足度およびアドヒアランスの変化についての研究
信一 今福 (2012)
10.12659/MSM.883544
Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patients
I. Açikbas (2012)
10.4172/2155-9554.1000421
Psoriasis and Fat-soluble Vitamins: A Review
Elizabeth Usedom (2017)
10.1016/1043-2760(93)90049-K
A dialogue on analogues Newer vitamin-D drugs for use in bone disease, psoriasis, and cancer
G. Jones (1993)
10.1046/j.1365-2133.1997.d01-1148.x
Comparative efficacy of calcipotriol (MC903) cream and betamethasone 17‐valerate cream in the treatment of chronic plaque psoriasis. A randomized, double‐blind, parallel group multicentre study
L. Molin (1997)
10.1016/j.ecl.2010.02.003
Vitamin D analogs.
G. Jones (2010)
10.2527/jas.2013-7237
Triennial Growth Symposium--Vitamin D: bones and beyond.
H. DeLuca (2014)
10.1016/0926-9959(94)00151-0
Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A randomised, double-blind, placebo-controlled, parallel group multi-centre study
C. Harrington (1996)
10.1111/j.1365-2133.1994.tb03382.x
Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp
C. Green (1994)
Le médicament du mois. L'association calcipotriol-dipropionate de bétamethasone (dovobet).
F. Henry (2005)
10.1016/S0738-081X(97)00010-2
Combinations and comparisons.
P. Kerkhof (1997)
10.1159/000066440
A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris
R. Kaufmann (2002)
10.1046/j.1365-2230.2002.01076.x
Nutritional factors and hair loss
D. Rushton (2002)
10.1046/j.1365-2133.2001.04075.x
Rationale for use and clinical responsiveness of hexafluoro‐1,25‐dihydroxyvitamin D3 for the treatment of plaque psoriasis: a pilot study
C. Durakovic (2001)
10.1007/978-3-642-55580-0_23
Vitamin D analogs and breast cancer.
J. O'kelly (2003)
10.4103/0378-6323.175919
Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review
R. Yan (2016)
10.1159/000063148
Topical Calcipotriol plus Oral Fumaric Acid Is More Effective and Faster Acting than Oral Fumaric Acid Monotherapy in the Treatment of Severe Chronic Plaque Psoriasis vulgaris
H. Gollnick (2002)
10.1007/978-3-642-78163-6_46
Vitamin D3 — Analoga
N. Sönnichsen (1993)
10.2310/7750.2010.09039
Psoriasis Care: New and Emerging Pharmacologic Trends
K. Papp (2010)
10.1046/j.1365-2133.1996.d01-1002.x
Vitamin D analogues in psoriasis: effects on systemic calcium homeostasis
J. Bourke (1996)
10.1046/j.1365-2133.1998.02071.x
The calcipotriol dose–irritation relationship: 48 hour occlusive testing in healthy volunteers using Finn Chambers®
Fullerton (1998)
10.1111/j.1365-2133.2004.05986.x
Efficacy of once‐daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris
K. Kragballe (2004)
10.1007/978-3-642-58308-7_14
Dithranol, Vitamin D 3 -Analoga und 8-Methoxypsoralen
M. Gloor (2000)
10.1111/j.1365-2133.1993.tb00188.x
Vitamin D analogues, marrow fibrosis and psoriasis
W. S. Douglas (1993)
10.1016/0006-2952(92)90630-2
Immunological properties of vitamin D analogues and metabolites.
L. Binderup (1992)
THE POTENT ANTIPROLIFERATIVE EFFECT OF 20-EPI ANALOGUES OF 1 , 25 DIHYDROXYVITAMIN D 3 IN HUMAN BREAST-CANCER MCF-7 CELLS IS RELATED TO PROMOTER SELECTIVITY
Christina (2006)
Diagnosis and management of psoriasis.
W. B. Kim (2017)
10.1111/jdv.13614
Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council
J. Wu (2016)
10.1016/S0190-9622(94)70272-1
Horizons in pharmacologic intervention in allergic contact dermatitis.
J. O. Funk (1994)
10.1007/978-3-662-09153-1_8
General Principles of Vitamin D Action and Mechanism-Based Search for Analogs with Specific Actions
H. F. Deluca (1995)
See more
Semantic Scholar Logo Some data provided by SemanticScholar